Company ProfilePremium

Regent Pacific Group Limited

Company Profile Analysis

Ticker: 0575.HK勵晶太平洋集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Regent Pacific Group Limited - Company showcase

Year Founded & Workforce

1990

17 Employees

Regent Pacific Group Limited logo

Regent Pacific Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Regent Pacific Group Limited Overview

MetricFY2023FY2024H1 2025
Employees (headcount, group excl. associate)—1717
Consultants—21

The 30 June 2024 and 30 June 2025 figures are the disclosed data points.

Regent Pacific is a micro-cap Hong Kong-listed holding company that has evolved from a 1990s emerging-markets fund manager and resources investor into a two-asset life-sciences platform.

The first asset is Plethora Solutions, the UK owner of Fortacin™/Senstend™. This is a topical lidocaine/prilocaine spray for premature ejaculation (PE). It is out-licensed to:

  • Recordati in Europe;

  • Jiangsu Wanbang Biopharmaceutical (a Fosun Pharma subsidiary) in China, where NMPA approval was granted on 16 June 2026;

  • Kobayashi Pharmaceutical in Japan.

The second asset is Deep Longevity, an AI "aging clock" software business (BloodAge, MindAge, BiometricAge, EpigeneticAge). It is now pivoting into US direct-to-consumer telehealth through Accrua™, launching in October 2026.

The group is capital-light but cash-constrained. It has had net liabilities since 2023, depends on loans from Galloway (a vehicle associated with controlling shareholder Jim Mellon), and carries a going-concern material uncertainty. The investment case is now a binary bet on Senstend™ China royalties (low-to-mid-teens royalties plus up to US$25M in sales milestones) and on Accrua's consumer traction.


Company's own description (Interim Report 2025, note 1 and note 4)

The company describes itself as "engaged in investment holding" with principal activities consisting of "investments in biopharma companies and other corporate investments." It reports two operating segments:

Biopharma: research, development, manufacturing, marketing and sale of pharmaceutical products, and development of AI systems for biological aging clocks.

Corporate Investment: investment in listed and unlisted corporate entities.

The Accrua press release (28 Sep 2026) describes Regent Pacific as "a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors." It states the group has returned approximately US$298 million to shareholders since its IPO in May 1997.

Independent characterisation

Functionally, Regent Pacific is a royalty-and-milestone licensor plus an early-stage SaaS business, run from a small Hong Kong head office with a UK pharma subsidiary and a US/global AI subsidiary. It does not manufacture, distribute or hold drug inventory.

Plethora (Fortacin™/Senstend™):

  • Value creation comes through out-licensing to regional pharma partners: Recordati (Europe), Wanbang/Fosun (China), Kobayashi (Japan), and South-East Asian licensees.

  • Partners fund registration and commercialisation; Plethora receives upfront and milestone payments plus royalties.

  • Manufacturing is contracted to third parties. Genetic S.p.A. signed a manufacturing and supply agreement to supply Senstend™ to Wanbang (announced after 30 Jun 2024). A "new manufacturer" is being qualified for South-East Asia.

  • The US is the largest unpartnered market. It requires a further Phase 3 study ("Study 008"), which management seeks to fund through an out-licence.

Deep Longevity (DLI):

  • Monetises proprietary deep-learning aging clocks through B2B SaaS (the SenoClock® platform) and per-report sales (AgeMetric™ / BloodAge© / MindAge© reports).

  • Customers are longevity clinics, laboratories, insurers and wellness platforms.

  • From October 2026, it adds a direct-to-consumer telehealth model (Accrua™). This model is expected to be largely subscription-based and recurring. Clinical delivery is outsourced to US telehealth infrastructure, physician and compounding-pharmacy partners.

Corporate Investment: This is now a residual. It held listed equities in Canadian and Australian dollars worth about US$2k and an unlisted HK club debenture worth about US$19k at 30 Jun 2025. It is also the cost centre carrying head-office G&A.

Revenue model mix (H1 2025, the latest pre-milestone period with full disclosure)

Revenue streamH1 2024 (USD K)H1 2025 (USD K)Model type
Royalty income (Fortacin™, mainly Recordati)80149Licensing / royalty
Deep Longevity subscription and support4387Subscription (SaaS)
Biological age reports01Transactional
Total revenue123237—

Source: Interim Report 2025, note 4.

In H1 2026, the mix shifted dramatically. The group recognised a net US$4.5M milestone (the US$5M NMPA approval milestone less PRC withholding tax) as revenue, per the positive profit alert of 3 Aug 2026. Licensing therefore represented more than 90% of H1 2026 revenue (derived).

Customer types and end-markets

BusinessCustomer typeEnd-market
Fortacin™ (EU)Recordati, which sells to pharmacies and prescribersMen's sexual health; leading markets Italy, Germany, France, Portugal
Senstend™ (China)Jiangsu Wanbang Biopharmaceutical (wholly controlled by Shanghai Fosun Pharmaceutical)Chinese PE market; first commercial sale expected H2 2026
Fortacin™ (Japan)Kobayashi Pharmaceutical Co., Ltd.Japan; clinical studies targeted to begin 2026
Fortacin™ (South-East Asia)Regional licensees (names not disclosed in reviewed documents)Selected South-East Asian countries
Deep Longevity B2BLongevity clinics, labs, insurers, wellness platforms (e.g. Humansa Health, HK; Holistica World, India)Longevity/wellness diagnostics
Accrua™ (D2C)US consumers in all 50 statesUS consumer telehealth: GLP-1 weight loss, peptides, HRT, testosterone

Strategy

Stated strategy themes (Interim Report 2025, Strategic Plan and Outlook)

The company states it will:

  1. Pursue commercialisation of Fortacin™/Senstend™ in the remaining key markets: China, the US, South-East Asia, Japan, Latin America and the Middle East.

  2. Commercialise deep-learning aging clocks and MindAge©, partnering with clinics, laboratories and insurers through AgeMetric™ reports and SaaS access.

  3. Continue strategic, value-led investments in healthcare and life sciences.

The Strategic Plan commits to:

  • divestment of non-core assets;

  • use of international and local expertise to tackle difficult markets;

  • use of the Hong Kong listing for liquidity and capital access while maintaining governance standards.

It also aims to return surplus capital through an effective dividend policy and share repurchases. This aim is aspirational given the capital deficiency.

Initiatives in the last 24 months

InitiativeDateDetailStatus
Senstend™ China NDA and approvalDec 2024 → 16 Jun 2026NDA filed; first-stage review passed 24 Mar 2025; approved Jun 2026Achieved
Senstend™ first commercial saleH2 2026 (guided)Triggers US$2M milestonePending
Fortacin™ US Phase 3 and out-licensing2025–2026Two CRO proposals evaluated; licensing talks targeted for end-2025Not yet announced
Kobayashi Japan clinical programme2,026Kobayashi to begin clinical studiesIn progress
South-East Asia supply transfer2025–2026New manufacturer variationsIn progress
Deep Longevity US expansionQ1 2026US sales team from 1 Jan 2026; CCO and VP Sales hired; target of 50+ US clients (exact target wording truncated in source)In progress
Deep Longevity product R&D2025–2026BiometricAge update; LLM upgrades; FaceAge in developmentIn progress
Accrua™ D2C telehealthAnnounced 28 Sep 2026; launch Oct 2026GLP-1, peptides, HRT, testosterone; subscription model; partner-deliveredLaunching
Balance-sheet repairApr–Jun 2025US$3.96M loan capitalisation; US$5M Galloway facilityCompleted / ongoing

ESG commitments: No quantified targets. An ESG report is included in the annual report per HKEX rules.

Cost programmes: Cost control measures are referenced in the going-concern basis. No numeric targets.

Medium-term financial targets: None published. There is no formal revenue or EBITDA guidance beyond milestone timing.

Products & Services

Biopharma: Plethora

ProductDescriptionKey specificationsTarget customerStatus / latest yearCommercial modelFlagship
Fortacin™ (EU/UK and other territories)Topical metered-dose spray for premature ejaculationProprietary formulation of lidocaine plus prilocaine (two marketed local anaesthetics); acts peripherally, not on the CNSMen with lifelong PE, via prescribers and pharmaciesEU approval c.2013; UK launch 2016; Recordati commercialising with uninterrupted supply (2025)Out-licence to Recordati; royalties (US$149k in H1 2025)Yes
Senstend™ (China)Same product, branded for ChinaImport licence (NDA) granted by NMPA on 16 Jun 2026; 4-year data protectionChinese PE patients via Wanbang/FosunApproved Jun 2026; first commercial sale expected H2 2026US$5M approval milestone (received/recognised); US$2M on first sale; up to US$25M sales milestones; tiered low-to-mid-teens royalties, subject to generic-entry adjustmentYes
Fortacin™ (US)Same productRequires further Phase 3 ("Study 008"); two CRO proposals evaluatedUS PE marketPre-Phase 3; out-licensing discussions ongoing (targeted by end-2025, not yet announced as of review)Seeking licensee to fund Phase 3Pipeline
Fortacin™ (Japan)Same productKobayashi progressing regulatory pathwayJapanese marketClinical studies targeted to begin 2026Out-licence to Kobayashi PharmaceuticalPipeline
Fortacin™ (South-East Asia)Same productLicensees negotiating regulatory variations and supply terms with a new manufacturerSelected South-East Asian countriesSupply transition ongoing (2025)Out-licence (licensee names not disclosed)—

Pricing: Not publicly disclosed by Regent Pacific or its licensees in the reviewed documents.

Market sizing claim: The 2024 Annual Report states an expectation of approximately 9 million patients in China in Senstend™'s first year, growing to over 170 million by year 10. This is company guidance and should be treated as aspirational.

Biopharma: Deep Longevity

OfferingDescriptionCapabilitiesTarget customerLaunch / latest versionPricing model
SenoClock® platformSaaS platform hosting all aging clocks and longevity recommendationsIntegrates multiple deep biomarkers of aging; "Longevity as a Service"Clinics, labs, insurers, enterprisesOngoing; LLM updated 2024–2025Subscription and support (US$87k in H1 2025)
BloodAge©Deep-learning biological age from routine blood testsPeer-reviewed: about 2,600 adults followed for a mean 9.2 years; each extra year of age gap associated with 15% higher mortality risk (Goshen et al., Aging and Disease, 2026)B2B and, from Oct 2026, D2C via AccruaUpdated continuouslyPer report / subscription
MindAge©Psychological/cognitive aging clockLLM-generated reportsB2BOngoingPer report / subscription
BiometricAgeBiometric aging clockUses 17 additional blood biomarkers plus 4 biometric measures (including blood pressure and waist circumference)B2BUpdated 2025Per report / subscription
EpigeneticAgeEpigenetic aging clockMethylation-basedB2BListed in 2025–2026 releases—
FaceAge / Face Index ScoreFacial-image aging clockIn R&DHealth, beauty and wellness"Upcoming" (2025–2026)—
AgeMetric™ reportsPackaged biological-age reportsReport outputs from clocksClinics, insurersOngoingPer report
Accrua™US D2C telehealth platform anchored to quarterly BloodAge measurementClinician-guided treatment: GLP-1 weight-loss medications, peptides, women's health (HRT), men's health (testosterone); HIPAA-compliant; LegitScript certification ahead of launch; all 50 statesUS consumersLaunch October 2026Largely subscription-based, recurring

Financial Narrative

Data hierarchy:

  • Company trading record (Interim Report 2025, p.57) for FY2021–FY2024.

  • S&P Global Market Intelligence (via StockAnalysis.com) for FY2025 and standardised lines.

  • Where the two differ, both are shown.

  • All figures are in US$ millions unless stated.

Income statement

Notes:

  • FY2025 finance costs are from S&P (US$0.37M). The company's FY2025 figure was not directly verified.

  • FY2025 net income is from S&P. FY2021–FY2024 net income is from the company trading record.

  • FY2021 net income benefited from about US$13.6M of gains on investment sales (S&P).

Margins

Revenue CAGR FY2021–FY2025: about -42% a year on S&P operating revenue (derived: 0.36/3.25 over 4 years). This figure is distorted by the FY2021 base, which included licence income.

Half-year bridge to the latest period

H1 2026 basis:

Revenue of about 5.28 is derived: from S&P TTM revenue of US$5.40M at Jun 2026 (5.40 − 0.36 + 0.24).

Net profit of about 0.55 is derived: from S&P TTM net income of −1.95 (−1.95 + 4.71 − 2.22). This sits inside the company's 3 Aug 2026 profit-alert range of US$0.5–1.0M.

  • The profit alert attributes the turnaround mainly to recognising a net US$4.5M milestone as revenue.

  • S&P also shows TTM income tax of about US$0.5M (consistent with PRC withholding tax) and TTM asset writedowns of about US$1.03M.

Balance sheet

Latest disclosed balance sheet (30 Jun 2025, Interim Report 2025):

  • Total assets: US$734k.

  • Cash: US$126k.

  • Trade receivables: US$220k.

  • Total liabilities: US$4.903M. These comprise payables and accruals of US$3.134M, shareholder loans of US$1.24M, lease liabilities of US$521k, and bank borrowing of US$8k.

  • Net current liabilities: US$4.146M.

  • Capital deficiency: US$4.169M.

It is likely more negative than −US$4.17M given the H2 2025 loss of about US$2.5M (derived) unless further capitalisations occurred.

Net debt: At 30 Jun 2025, net debt was about US$1.64M (derived: shareholder loans 1.24 + bank 0.008 + leases 0.52 − cash 0.126). Leases are included.

Cash flow

Disclosed half-year cash flows:

  • H1 2025 operating cash outflow: US$2.161M (H1 2024: US$2.555M).

  • H1 2025 capex: US$14k (computer equipment).

  • H1 2025 shareholder loan drawdowns: US$2.48M (H1 2024: US$0.72M).

  • H1 2024 included US$217k proceeds from investment disposals.

Ratios

Ratio notes:

ROE: is not meaningful because equity is negative. A vendor (Wisesheets) reports a TTM ROE of 87%, which is an artefact of a loss divided by negative equity.

Current ratio: for FY2024 is derived (601 / 5,649).

Interest coverage: is derived from S&P EBIT and company finance costs.

  • ROA, ROIC, debt/equity, net debt/EBITDA, asset turnover and cash conversion cycle are not meaningful (negative equity and negative EBITDA) or not disclosed.

Commentary on trends, inflections and drivers

Three distinct financial regimes.

FY2021–FY2023: Large accounting losses: Losses of US$12.6M–36.4M a year were dominated by non-cash amortisation of the Fortacin™ intangible (about US$22–25M a year). FY2021 was flattered by about US$13.6M of investment gains, and FY2022 was hit by about US$4.1M of investment losses. Underlying cash burn (S&P EBITDA) was a steady US$5–6M a year.

FY2024–FY2025: Lean cash-burn shell: With the patent fully amortised on 19 Nov 2023, reported losses collapsed to about US$4.5–4.7M. This roughly equals G&A plus R&D less small royalty and SaaS income. Cash fell from US$2.10M (FY2023) to about US$0.1M (FY2024–FY2025). The group was funded by Galloway shareholder loans at 8–12%, which pushed finance costs up (to US$0.37M in FY2025 per S&P). Equity turned negative at FY2023 (−US$1.55M) and reached −US$5.90M by FY2024. The June 2025 debt-for-equity swap (US$3.96M) only partially repaired this.

H1 2026: Milestone-driven inflection: The NMPA approval of Senstend™ converted a US$5M contingent milestone into revenue (US$4.5M net of withholding). This produced the first half-year profit in the reviewed history (US$0.5–1.0M guided; about US$0.55M implied by S&P TTM data).

The key analytical point is that the recurring run-rate is still loss-making. H1 2025 recurring revenue was US$237k against about US$2.25M of operating and R&D costs. Sustainable profitability therefore depends on Senstend™ royalties scaling from H2 2026 and on Accrua™ achieving consumer traction.

Going concern. Every period reviewed carries a material uncertainty. In the 2025 interim, directors relied on the US$5M Galloway facility (12%, 12-month term from 20 Mar 2025) and cost controls, with a cash-flow forecast through 30 Sep 2026. The receipt of the US$5M milestone in H2 2026 should materially ease this pressure. Confirmation should be sought in the 2026 interim report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Entity / Unit Details

Entity / unitFunctionOwnershipLocation

Regent Pacific Group Limited

Listed holding company, head office, Corporate Investment segment

Listed

Cayman (incorporated) / Hong Kong (HQ)

Plethora Solutions (Plethora Solutions Holdings and subsidiaries)

Fortacin™/Senstend™ IP owner and licensor

100% (wholly-owned UK subsidiary)

United Kingdom (London historically)

Deep Longevity, Inc. and subsidiaries

AI aging clocks, SenoClock® SaaS, Accrua™ D2C

100% (acquired 2020)

Global; US commercial team from 1 Jan 2026

Associate (unnamed)

Carrying value US$1k

Associate

—

Segment revenue (USD K)

Segment revenue (USD K)H1 2024H1 2025

Biopharma

123237

Corporate Investment

00

Total

123237

Results by Segment

Segment result (USD K)H1 2024H1 2025

Biopharma segment loss

-655-325

Corporate Investment segment loss

-1,902-1,683

Total segment loss (loss from operations)

-2,557-2,008

Finance costs

-64-207

Loss before tax

-2,621-2,215

Segment Assets & Liabilities

Segment balance (USD K)FY2024 (31 Dec)H1 2025 (30 Jun)

Biopharma segment assets

278353

Corporate Investment segment assets

331380

Biopharma segment liabilities

208241

Corporate Investment segment liabilities

2,9762,901

Segment revenue (USD Mn)

Segment revenue (USD Mn)FY2023FY2024FY2025

Biopharma

0.290.720.36

Corporate Investment

000

Revenue by Segment

Plethora (GBP K)H1 2024H1 2025

Royalty income

63115

R&D (US FDA / Phase 3 related)

-144-70

G&A

-129-124

Operating loss

-210-79

Cash at period end

—23

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue, S&P operating revenue (USD Mn)

3.250.110.290.720.36

Total revenue plus FV gain/(loss), company trading record (USD Mn)

18.24-4.020.540.660.35

Gross profit, S&P (USD Mn)

0.85-1.11-1.09-0.22-0.42

Operating income, S&P (USD Mn)

-28.77-30.77-27.95-4.19-4.30

Amortisation of intangibles (USD Mn)

23.7624.9522.1800

EBITDA, S&P (USD Mn)

-4.98-5.81-5.75-4.18-4.29

Finance costs, company (USD Mn)

1.221.010.080.170.37

Pre-tax income (USD Mn)

-15.09-36.01-30.46-4.51-4.71

Income tax credit/(expense) (USD Mn)

2.49-0.425.410.030

Net income attributable (USD Mn)

-12.60-36.43-25.05-4.48-4.71

EPS basic, S&P (USD)

-0.11-0.30-0.11-0.02-0.02

EPS diluted, S&P (USD)

-0.11-0.30-0.11-0.02-0.02

Dividends per share (USD)

00000

Weighted shares, S&P (M, post-consolidation basis)

120120225228261

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin, S&P (%)

26.1——-30.5-115.7

Operating margin, S&P (%)

-884-26,995-9,605-583-1,184

Net margin, S&P (%)

-387-31,954-8,608-623-1,298

EBITDA margin, S&P (%)

-153————

Income Statement

MetricH1 2024H1 2025H1 2026

Revenue (USD Mn)

0.120.245.28

R&D expenditure (USD Mn)

0.530.38—

G&A expenditure (USD Mn)

2.011.87—

Finance costs (USD Mn)

0.060.21—

Net profit/(loss) (USD Mn)

-2.62-2.220.55

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (USD Mn)

———0.61—

Total current assets, S&P (USD Mn)

12.792.312.790.600.56

Cash and equivalents (USD Mn)

0.610.312.100.100.14

Trading securities (USD Mn)

10.511.100.320.020.02

Shareholder loans (USD Mn)

——02.57—

Bank borrowings, UK Bounce Back Loan (USD Mn)

———0.011—

Lease liabilities (USD Mn)

———0.76—

Total equity / (capital deficiency) (USD Mn)

——-1.55-5.90—

Goodwill and intangibles (USD Mn)

——000

Working capital (USD Mn)

———-5.05—

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Free cash flow, S&P (USD Mn)

-1.750.49-3.81-4.13-4.31

Dividends paid (USD Mn)

00000

Buybacks (USD Mn)

00000

Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE (%)

——

n/m

n/m

n/m

Current ratio (x)

———0.11—

Interest coverage, EBIT/interest (x)

-23.6-30.5-349-24.6-11.6

Region revenue (USD K)

Region revenue (USD K)H1 2024H1 2025

Europe

86169

United States

124

Middle East

08

Asia Pacific

2556

Total

123237

Region Overview

RegionYoY growth (%)

Europe

96.5

United States

-66.7

Middle East Details

Middle Eastn/m (from zero)

Asia Pacific

124.0

Share Price History

DatePrice (HKD)Source

19 May 1997 (IPO)

2.62

etnet

22 Nov 2024

0.40

etnet

18 Dec 2024

0.33

MT Newswires

7 Apr 2025

0.485

Interim Report 2025 (capitalisation price)

Apr 2026 (approx.)

0.61

etnet quote page

30 Jul 2026

0.92

StockAnalysis.com

9 Oct 2026

0.875

StockAnalysis.com

Valuation Snapshot

MultipleValueBasis

Market cap

about US$32.7M

291.8M shares × HK$0.875 ÷ 7.80

EV

about US$34M

Market cap plus about US$1.6M net debt (Jun 2025 basis; stale)

EV / Sales (TTM Jun 2026)

about 6.3x

TTM revenue US$5.4M (milestone-inflated)

EV / Sales (FY2025)

about 94x

Revenue US$0.36M

P/E

n/m

TTM loss (−US$1.95M)

EV / EBITDA

n/m

TTM EBITDA about US$0.14M (milestone-driven)

P/B

n/m

Negative equity

Capital Markets

ItemStatus

Analyst consensus

None; no sell-side coverage identified

Dividend history and policy

No dividends in FY2020–FY2025 or H1 2026. Policy: return surplus capital via "an effective dividend policy and share repurchase programme" (aspirational). About US$298M returned to shareholders since the 1997 IPO.

Buybacks

General repurchase mandate approved at the 19 Jun 2025 AGM; no repurchases disclosed

Credit ratings

None (Moody's / S&P / Fitch: not rated)

Debt maturity profile

Galloway facility: 12-month term from 20 Mar 2025, extendable by mutual consent (US$1.24M drawn at 30 Jun 2025). UK Bounce Back Loan: fully repaid by May 2026 (US$8k outstanding at Jun 2025). Leases: US$479k current, US$42k non-current.

Analyst Conclusions

Management guidance

There is no numeric earnings guidance. Stated milestones are:

  • first commercial sale of Senstend™ in China in H2 2026, triggering a US$2M milestone;

  • US Fortacin™ Phase 3 start and out-licensing;

  • Kobayashi Japan clinical studies in 2026;

  • Deep Longevity's US scale-up and Accrua™ launch in October 2026.

There is no consensus, as no analysts cover the stock.

Bull case

  1. China royalty annuity. Senstend™ is approved and partnered with Fosun's Wanbang. Low-to-mid-teens royalties plus up to US$25M in sales milestones could exceed the current US$33M market cap if Chinese uptake approaches even a fraction of management's patient projections.

  2. Self-funding inflection. The net US$4.5M milestone produced H1 2026 profitability. The US$2M first-sale milestone and royalties could cover the roughly US$4–5M annual cost base, removing dilution risk.

  3. Accrua™ optionality. A capital-light D2C model on partner infrastructure, anchored to validated BloodAge science, enters a market where peers have scaled to hundreds of millions of dollars of revenue quickly.

Bear case

  1. Recurring economics remain sub-scale. H1 2025 recurring revenue was US$237k. Excluding the one-off milestone, the business still loses about US$4M a year, and equity was negative at the last verified date.

  2. Short and fragile exclusivity. China protection is 4 years with generic adjustment, against entrenched cheap dapoxetine generics. The US programme has repeatedly missed out-licensing targets.

  3. Controlled, illiquid micro-cap. Mellon interests hold about 57–66%, funding comes from a related party, and there is no analyst coverage. Telehealth entry is high-burn and regulatorily exposed, so it could absorb the milestone cash.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Senstend™ first commercial sale in China and US$2M milestoneH2 2026
2026 interim report: confirmation of equity position, going-concern language, Galloway balancePublished Aug–Sep 2026 (verify)
Early Chinese prescription and royalty dataH1 2027 results (Mar 2027)
Accrua™ subscriber metrics and marketing spendFrom Q4 2026
US Fortacin™ out-licence announcementOpen-ended
Kobayashi Japan clinical trial initiation2026–2027
Any equity issuance or new share scheme (2016 scheme expired)Ongoing
Clarification of the PitchBook-listed "FZCO/CCEC" JVUnconfirmed

Concluding analyst verdict

Regent Pacific has spent a decade converting a legacy fund-management and resources vehicle into a narrowly focused life-sciences holding company. The June 2026 NMPA approval of Senstend™ is the first unambiguous proof that the Plethora licensing model can deliver.

The transaction structure is attractive. Fosun's Wanbang bears all Chinese commercialisation cost, while Regent Pacific collects milestones and low-to-mid-teens royalties on a product with a differentiated, non-systemic mechanism. The US$4.5M net milestone alone was roughly the group's full annual cash burn and delivered its first half-year profit in the reviewed history.

The equity story nevertheless remains high-risk. Before the milestone, the group operated with:

  • about US$0.1M of cash;

  • negative equity of US$4–6M;

  • a going-concern material uncertainty;

  • dependence on a lender associated with its controlling shareholder.

Recurring revenue (EU royalties plus Deep Longevity SaaS) is still well under US$1M a year. The longer-dated value drivers each carry significant execution risk: Chinese royalties face generics after four years of data protection, the US Fortacin™ programme has no partner, and Accrua™ is a late entrant to a crowded, heavily regulated telehealth market.

At about US$33M market capitalisation, the market is pricing a moderately successful China launch plus some Accrua™ optionality. That is reasonable but not obviously cheap, because the lack of disclosed royalty forecasts makes the China value hard to underwrite.

The decisive datapoints over the next 12 months are:

  1. timing of the first Chinese sale;

  2. the first reported royalty line;

  3. whether management uses milestone cash to restore positive equity rather than fund aggressive US consumer marketing.

Until royalties are visible, the company is best viewed as a speculative, controlled micro-cap whose fundamental floor is set by Senstend™ economics and whose upside depends on management delivering partnering milestones that have historically slipped.

Confidence note: FY2025 and H1 2026 figures rely partly on S&P-standardised data and the company's profit alert. Final audited and interim statements should be checked for exact balance-sheet values.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / notesBackground

James (Jim) Mellon

Non-Executive Chairman

Co-founder (1990); Chairman since 2002

Oxford PPE (Masters, 1978); founder of Burnbrae, UraMin and Manx Financial; former Plethora chairman (2012–2016); controlling shareholder

Jamie Alexander Gibson

Executive Director and CEO

—

Born 1966; drives licensing and Deep Longevity strategy

Jayne Allison Sutcliffe

Non-Executive Director

Nomination Committee member from 30 Jun 2025

Mellon associate (Charlemagne/Burnbrae group, per public records)

Stawell Mark Searle

Independent Non-Executive Director

——

Adrian Alan Chan Wan Tsun

Independent Non-Executive Director

Founded One Business Group (fractional C-suite platform) from 1 Jun 2025

Former regional director, The CFO (HK) Ltd

Ihsan Al Chalabi

Independent Non-Executive Director

Adjunct Professor, Biomedical Sciences, City University of Hong Kong (from 1 Jan 2025); Nomination Committee from 30 Jun 2025

—

Executive Leadership Team

NameTitleBornNotes

Dr Michael Grant Wyllie

Co-founder (Plethora) and Chief Scientific Officer

1,951

Urology pharmacologist

Yui Fui Wong

Chief Financial Officer

1,975—

Paul Eric Jones

Investment Director

1,965

BA, MBA

Lui Mei Yan (Winnie)

Company Secretary

1,975—

Prof John M. Fitzpatrick

Chairman, Clinical Scientific Advisory Board

—

Senior urologist

Deepankar Nayak

CEO, Deep Longevity

—

Consultant via FOKI Limited (options granted 3 May 2023)

Dylan Kay

Chief Commercial Officer (US), Deep Longevity

——

Luke Shaffer

VP Sales (US), Deep Longevity

—

Appointed late 2025

Directors' Remuneration

NameTotal pay (USD)Basis

Jamie Gibson

about 1.0–1.32M (vendor figures vary by currency conversion and year)

Yahoo Finance (latest annual report)

Michael Wyllie

about 182–198k

Yahoo Finance

Key management (aggregate)

800k (H1 2025); 788k (H1 2024)

Interim Report 2025, note 19

Major Shareholders

HolderShares%Date / basis

James Mellon (direct and through associates)

129,153,58456.56

31 Dec 2023 (etnet)

Galloway (lender; Mellon-associated vehicle per prior disclosures)

+63,377,163 capitalisation shares

—

Issued 25 Jun 2025

Mellon-concert group, pro forma

about 192.5M

about 66

Derived (assumes Galloway is within the Mellon interest; verify against the latest SFO filings)

Institutional ownership (top 10)

——

No meaningful institutional register disclosed

Free float

about 34

—

Derived

Competitive Landscape

Key Competitors

CompetitorProductPositioning vs Fortacin™/Senstend™

A. Menarini (private)

Priligy® (dapoxetine, oral SSRI)

Systemic, on-demand oral; established in EU and Asia; CNS side-effect profile vs Fortacin's topical action

Chinese dapoxetine generics (multiple domestic manufacturers)

Generic dapoxetine

Low-cost incumbents in China; key price competitors to Senstend™

Absorption Pharmaceuticals (Promescent)

OTC lidocaine spray (US)

OTC topical; competes in the US where Fortacin™ is unapproved

Generic EMLA®-type lidocaine/prilocaine creams

Off-label topical anaesthetics

Cheap but messy; risk of partner transfer

OTC benzocaine and lidocaine wipes and sprays (various brands)

Consumer products

Low-price substitutes

Off-label daily SSRIs and tramadol (generic)

Systemic

Physician-prescribed alternatives

Hims & Hers / Ro (telehealth)

Prescription PE regimens (e.g. sertraline, topical sprays)

Channel competitors in the US

TruDiagnostic

Epigenetic age testing (TruAge)

Leading US epigenetic clock lab

Tally Health

Consumer epigenetic test

D2C

GlycanAge

Glycan-based biological age

Clinic channel

Elysium Health

Index (epigenetic age)

Consumer

InsideTracker

Blood-based "InnerAge"

Consumer/athlete

Function Health

Broad blood panels

Large US consumer base

Humanity / various apps

Wearable-based age scores

Free/low-cost

Competitor Detail

MetricRegent Pacific

Revenue (latest FY)

US$0.36M (FY2025, S&P)

Growth

−50% (FY2025)

Operating margin

−1,184%

R&D intensity

about 161% of revenue (H1 2025)

Company Snapshot

17

Employees

$32.7M

Market Cap

1990

Founded

Queen's Road Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Regulatory approval in China: NMPA approved Senstend™ on 16 Jun 2026, triggering a US$5M milestone (HKEX, 16 Jun 2026).
  • Tier-1 partners: Wanbang is wholly controlled by Fosun Pharma; Recordati commercialises in the EU; Kobayashi holds Japan.
  • Economics of royalties: Tiered low-to-mid-teens royalties plus up to US$25M in sales milestones and a US$2M first-sale milestone, all without carrying commercial costs.
  • Growing EU royalty stream: Plethora royalties rose from GBP 63k (H1 2024) to GBP 115k (H1 2025), up 83%.
  • Scientific validation of BloodAge: Peer-reviewed study of about 2,600 adults over 9.2 years linking each age-gap year to 15% higher mortality risk (Aging and Disease, 2026).
  • Supportive controlling shareholder: Galloway capitalised US$3.96M of loans (Jun 2025) and provided a US$5M facility (Mar 2025).
  • Lean cost base: 17 employees; H1 2025 operating loss cut to US$2.01M from US$2.56M.

Weaknesses

  • Negative equity: Capital deficiency of US$4.17M (30 Jun 2025); US$5.90M (31 Dec 2024).
  • Going-concern material uncertainty in every recent report.
  • Tiny recurring revenue: US$237k in H1 2025 against about US$2.25M of operating and R&D costs.
  • Cash scarcity: US$126k cash at 30 Jun 2025.
  • Concentration: One customer (Customer A, the royalty payer) accounted for 63% of H1 2025 revenue.
  • Expensive related-party debt at 8–12%; finance costs more than tripled in H1 2025 (US$207k vs US$64k).
  • US Fortacin™ programme stalled: Out-licence "with a view to having these finalised by end-2025" had not been announced by Oct 2026.

Opportunities

  • China royalties from first commercial sale (H2 2026), plus the US$2M milestone.
  • Up to US$25M of China sales milestones.
  • Accrua™ entry into US D2C telehealth, a market validated by MEDVi's about US$1.8B run-rate.
  • A US Fortacin™ out-licence funding the Phase 3 Study 008.
  • Japan (Kobayashi clinical start 2026) and South-East Asia supply restart.
  • Insurer and employer adoption of aging clocks (Deep Longevity's US four-channel strategy).
  • Use of the milestone cash to deleverage and restore positive equity.

Threats

  • Generic entry in China after the 4-year data protection lapses, with royalty adjustment clauses.
  • Price competition from dapoxetine generics in China.
  • US regulatory tightening on compounded GLP-1s and telehealth prescribing, directly affecting Accrua's treatment menu.
  • High customer acquisition costs against well-capitalised telehealth incumbents.
  • Supply-chain risk: dependence on a single contract manufacturer per region; the South-East Asia supply interruption is ongoing.
  • Dilution: past share issuance (rights issue 2023; 63M shares in 2025) and likely future equity needs.
  • Key-person and controlling-shareholder dependence on Jim Mellon.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
20 Mar 2025Galloway grants a US$5M unsecured facility at 12%; agrees not to demand the US$2M loan at maturityUnderpins going concern
24 Mar 2025NMPA confirms the Senstend™ NDA passed first-stage reviewDe-risks China approval
27 Mar 2025FY2024 results: loss US$4.48M (vs US$25.05M)Post-amortisation cost base revealed
Mar 2025Full settlement of 2018–2024 China regulatory costs advanced on behalf of WanbangClears receivable; cash inflow (disclosed in Jul 2026 supplement)
7 Apr 2025Debt Settlement Agreement with Galloway (HK$0.485 per share)Balance-sheet repair
28 Apr 20252024 Annual Report publishedIncludes China patient-volume ambition
16 May 2025Circular for loan capitalisation (specific mandate)Governance step
1 Jun 2025INED Adrian Chan's external role changes (founds One Business Group)Director information update
19 Jun 2025AGM and EGM: all resolutions passed (auditor reappointment, director re-elections, issue/buyback mandates, capitalisation)Shareholder approval
25 Jun 2025Loan capitalisation completed: 63.38M shares issuedDeficiency cut to US$4.17M
30 Jun 2025Sutcliffe and Al Chalabi join the Nomination CommitteeGovernance
H1 2025Deep Longevity onboards Humansa (HK) and Holistica (India); usage up YoY; BiometricAge updateCommercial traction
27 Aug 20252025 interim results: revenue US$237k (+93%); loss US$2.215M (−15%)Narrowing losses
22 Sep 20252025 Interim Report publishedDetailed disclosures
–Deep Longevity appoints Dylan Kay (US CCO) and Luke Shaffer (US VP Sales)US go-to-market
–Announcement of Deep Longevity's US market entry in Q1 2026Strategic expansion
19 Dec 2025Revised Audit Committee terms of referenceGovernance
1 Jan 2026First two US sales representatives startExecution
16 Mar 2026Board meeting notice for FY2025 resultsRoutine
26 Mar 2026FY2025 audited results: net loss about US$4.71M (S&P)Continued burn pre-milestone
15 Apr 2026"(FZCO/CCEC) Joint Venture" per PitchBookUnconfirmed
9 Jun 20262016 Share Option Scheme expiresNo scheme in force unless replaced
16 Jun 2026NMPA approves Senstend™; US$5M milestone triggered; 4-year data protection; up to US$25M sales milestones; low-to-mid-teens royaltiesTransformational event
9 Jul 2026Supplementary announcement to the 2025 Annual Report on lower prepayments and receivablesDisclosure clean-up
3 Aug 2026Positive profit alert: H1 2026 profit of US$0.5–1.0MFirst profit in years
2026Peer-reviewed BloodAge study in *Aging and Disease*Scientific validation
Aug 20262026 interim results (board meeting called; final figures not directly reviewed)Confirms milestone accounting
2026Deep Longevity named Runner-Up in the Nestlé VITAL Smart Aging Global ChallengeValidation
28 Sep 2026Accrua™ announced; launch October 2026 in all 50 US statesNew D2C revenue line

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Total revenue plus FV gain/(loss), company trading record fell from USD 18.2 Mn in FY2021 to USD 0.4 Mn in FY2025.
Regent Pacific Group Limited — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Total revenue plus FV gain/(loss), company trading record18.2-40.50.70.4
Revenue, S&P operating revenue3.30.10.30.70.4
Gross profit, S&P0.9-1.1-1.1-0.2-0.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.